glp 1 agonist alzheimer GLP-1 RA in Diabetes-Related Neurodegenerative Diseases | DDDT Popular obesity drug fails in

The authors also suggest a second potential pathway independent of GLP-1 for some of the cardiovascular effects

doi: 10.1177/10600280231205490

Reprod Sci (2021) 28(2):32231

GLP-1

Telling signs that its working would include a gradual decrease in blood sugar levels and a reduction in symptoms associated with high blood sugar such as frequent urination, fatigue, and blurred vision

The science of slowed gastrointestinal motility GLP-1 receptor agonists act on the gutbrain axis and are known to slow gastric emptying and overall gastrointestinal transit , contributing to early satiety and appetite suppression. As intestinal transit slows, the colon has more time to absorb water from stool , leading to hard, dry stools that are difficult to pass . Constipation is a common, dose-related adverse effect listed in FDA prescribing information for both Wegovy (semaglutide) and Zepbound (tirzepatide) and is most frequently reported during dose escalation , with improvement over time., Step-by-Step MD Protocol for Relief 1